Allen M, Karplus P, Mehl R, Cooley R
Chem Rev. 2024; 124(10):6592-6642.
PMID: 38691379
PMC: 11658404.
DOI: 10.1021/acs.chemrev.4c00110.
Arbaciauskaite M, Pirhanov A, Ammermann E, Lei Y, Cho Y
Protein Eng Des Sel. 2023; 36.
PMID: 37294629
PMC: 10281017.
DOI: 10.1093/protein/gzad005.
Allen G, Grahn A, Kourentzi K, Willson R, Waldrop S, Guo J
Front Microbiol. 2022; 13:961093.
PMID: 36003937
PMC: 9393631.
DOI: 10.3389/fmicb.2022.961093.
Fei C, Nie L, Zhang J, Chen J
Front Immunol. 2021; 12:771231.
PMID: 34868030
PMC: 8635192.
DOI: 10.3389/fimmu.2021.771231.
Jones K, Chapman A, Driscoll H, Fuller E, Kelly M, Li X
Biotechniques. 2021; 72(1):11-20.
PMID: 34841898
PMC: 10568613.
DOI: 10.2144/btn-2021-0078.
Engineering of a Small Protein Scaffold To Recognize Sulfotyrosine with High Specificity.
Lawrie J, Waldrop S, Morozov A, Niu W, Guo J
ACS Chem Biol. 2021; 16(8):1508-1517.
PMID: 34251168
PMC: 8785239.
DOI: 10.1021/acschembio.1c00382.
Ovalbumin Antigen-Specific Activation of Human T Cell Receptor Closely Resembles Soluble Antibody Stimulation as Revealed by BOOST Phosphotyrosine Proteomics.
Chua X, Salomon A
J Proteome Res. 2021; 20(6):3330-3344.
PMID: 34018748
PMC: 8626127.
DOI: 10.1021/acs.jproteome.1c00239.
Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated Aβ Species in a Mouse Model of Alzheimer's Disease.
Kumar S, Kapadia A, Theil S, Joshi P, Riffel F, Heneka M
Front Mol Neurosci. 2021; 13:619639.
PMID: 33519377
PMC: 7844098.
DOI: 10.3389/fnmol.2020.619639.
Synthesis and Evaluation of Non-Hydrolyzable Phospho-Lysine Peptide Mimics.
Hauser A, Poulou E, Muller F, Schmieder P, Hackenberger C
Chemistry. 2020; 27(7):2326-2331.
PMID: 32986895
PMC: 7898648.
DOI: 10.1002/chem.202003947.
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth.
Vidimar V, Beilhartz G, Park M, Biancucci M, Kieffer M, Gius D
Proc Natl Acad Sci U S A. 2020; 117(29):16938-16948.
PMID: 32616570
PMC: 7382267.
DOI: 10.1073/pnas.2000312117.
Protein Phosphorylation in Serine Residues Correlates with Progression from Precancerous Lesions to Cervical Cancer in Mexican Patients.
Padilla-Mendoza J, Contis-Montes de Oca A, Rodriguez M, Lopez-Casamichana M, Bolanos J, Quintas-Granados L
Biomed Res Int. 2020; 2020:5058928.
PMID: 32337254
PMC: 7157794.
DOI: 10.1155/2020/5058928.
Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers.
Abramczyk H, Imiela A, Brozek-Pluska B, Kopec M, Surmacki J, Sliwinska A
Cancers (Basel). 2019; 11(12).
PMID: 31847192
PMC: 6966530.
DOI: 10.3390/cancers11122017.
Selection and characterization of FcεRI phospho-ITAM specific antibodies.
Velappan N, Mahajan A, Naranjo L, Velappan P, Andrews N, Tiee N
MAbs. 2019; 11(7):1206-1218.
PMID: 31311408
PMC: 6748597.
DOI: 10.1080/19420862.2019.1632113.
Next-generation antibodies for post-translational modifications.
Hattori T, Koide S
Curr Opin Struct Biol. 2018; 51:141-148.
PMID: 29753204
PMC: 6686900.
DOI: 10.1016/j.sbi.2018.04.006.
Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K, Tohme Y, Srinivasiah A, Taylor-Parker J, Harrington Y, Shah A
J Histochem Cytochem. 2018; 66(8):549-561.
PMID: 29587004
PMC: 6071180.
DOI: 10.1369/0022155418766503.
study on the role of SOX9 in trastuzumab resistance of adenocarcinoma of the esophagogastric junction.
Hong Y, Chen H, Rao Z, Peng B, Hu H, Lin S
Exp Ther Med. 2018; 15(3):3103-3107.
PMID: 29456713
PMC: 5795639.
DOI: 10.3892/etm.2018.5744.
Development of SH2 probes and pull-down assays to detect pathogen-induced, site-specific tyrosine phosphorylation of the TLR adaptor SCIMP.
Luo L, Tong S, Wall A, Khromykh T, Sweet M, Stow J
Immunol Cell Biol. 2017; 95(6):564-570.
PMID: 28290451
DOI: 10.1038/icb.2017.10.
Systems Biology to Support Nanomaterial Grouping.
Riebeling C, Jungnickel H, Luch A, Haase A
Adv Exp Med Biol. 2017; 947:143-171.
PMID: 28168668
DOI: 10.1007/978-3-319-47754-1_6.
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.
Lion M, Harle A, Salleron J, Ramacci C, Campone M, Merlin J
Oncol Lett. 2016; 12(3):2028-2032.
PMID: 27602133
PMC: 4998521.
DOI: 10.3892/ol.2016.4891.
Rational design and validation of an anti-protein kinase C active-state specific antibody based on conformational changes.
Pena D, de Andrade V, Silva G, Neves J, de Oliveira P, Alves M
Sci Rep. 2016; 6:22114.
PMID: 26911897
PMC: 4766434.
DOI: 10.1038/srep22114.